Arylpiperazines having activity at the serotonin 1A receptor
AssigneeEli Lilly and Company
InventorsDaniel Timothy Kohlman, Yao-Chang Xu
Life of this patent
Estimating the term…
Abstract
A series of aryl piperazine compounds of the formula: or the pharmaceutically acceptable salts thereof, are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
Claims8
A compound of the formula:
- or the pharmaceutically acceptable salts thereof.
A compound which is (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine and the pharmaceutically acceptable salts thereof.
A compound which is (+)-1-(2-methoxyphenyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine monohydrochloride.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.